CA Patent

CA3154024C — Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma

Assigned to Pharmacyclics LLC · Expires 2024-02-27 · 2y expired

What this patent protects

Disclosed herein are uses of a compound (ibrutinib) for treating follicular lymphoma, wherein the compound has the structure:

USPTO Abstract

Disclosed herein are uses of a compound (ibrutinib) for treating follicular lymphoma, wherein the compound has the structure:

Drugs covered by this patent

Patent Metadata

Patent number
CA3154024C
Jurisdiction
CA
Classification
—
Expires
2024-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.